Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer [Yahoo! Finance]
Qualigen Therapeutics, Inc. (QLGN)
Company Research
Source: Yahoo! Finance
of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad , MD, MBA as Chief Medical Officer. Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of strategic planning, clinical development, and commercialization. "We are thrilled to appoint Dr. Arshad as Bexion's Chief Medical Officer," said Scott Shively , Bexion's Chief Executive Officer. "With over 25 years in the biotechnology and pharmaceutical industry, Dr. Arshad's immense experience will greatly benefit our team as we move forward with our mCRC and CIPN clinical programs. We are eager to leverage his extensive skill set and welcome him on board." This is a very exciting time to join Bexion with the evaluation of BXQ-350 for the treatment of mCRC and CIPN firmly in the clinic," said Dr. Arshad, "I am eager to drive the clinical programs forward and develop a potential first-in-class prod
Show less
Read more
Impact Snapshot
Event Time:
QLGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QLGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QLGN alerts
High impacting Qualigen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
QLGN
News
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ [Yahoo! Finance]Yahoo! Finance
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™GlobeNewswire
- Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingGlobeNewswire
QLGN
Sec Filings
- 5/6/24 - Form S-1/A
- 5/3/24 - Form 424B3
- 5/3/24 - Form EFFECT
- QLGN's page on the SEC website